Microfluidic Organoids Could Revolutionize Breast Cancer Treatment

Breast cancer is the most common tumor among women worldwide and has a profound impact on individuals and society. Aside from being a leading cause of cancer-related death, patients often undergo invasive treatments such as surgery, radiation, and chemotherapy, which may result in long-term side effects and reduced quality of life. Additionally, the healthcare burden of breast cancer is immense. This makes effective, timely, and personalized treatments a critical need.

A recent study published in Scientific Reports presents a microfluidic-based method for growing breast cancer organoids that significantly reduces the culture time while maintaining essential structural and drug response characteristics. This method could be the key to developing personalized breast cancer treatments in the future.

Continue reading “Microfluidic Organoids Could Revolutionize Breast Cancer Treatment”

There’s a Vaccine for That—Could mRNA Vaccines be Used to Prevent Cancer Recurrence?

mRNA vaccines came roaring onto the public stage in 2020. In the United States and Europe, two of the vaccines that are being used against the SARS-CoV-2 virus are mRNA vaccines. The scientific community has been talking about the potential of this technology against infectious diseases as well as cancer for several years, but no one thought that the first mRNA vaccines would make such a huge, and public, debut.

One big benefit of mRNA vaccines is the speed at which they can be developed. mRNA vaccines use messenger RNA particles to teach our cells to make a bit of protein, which then triggers our body’s immune response, and it is relatively easy to synthesize large amounts of mRNA in a laboratory. As promising as this sounds for infectious diseases, the application of mRNA vaccines for oncology might be even more exciting.

Could mRNA vaccines be used for personalized cancer vaccines?
Continue reading “There’s a Vaccine for That—Could mRNA Vaccines be Used to Prevent Cancer Recurrence?”

MSI Testing of Tumor Cells for Better Tailored Treatment

3D artistic rendering of mismatch repair. Microsatellite instability (MSI)  which can result from defects in mismatch repair is a biomarker for some cancers

There are as many different cancers as there are people with cancer. Unlike infectious diseases, which are caused by pathogens that are foreign to our bodies (bacteria, viruses, parasites), cancer cells arise from our body—our own cells gone rogue. Because cancer is a dysfunction of a person’s normal cells, every cancer reflects the genetic differences that mark us as individuals. Add to that environmental influences like diet, tobacco use, the microbiome and even occupation, and the likelihood of finding a “single” pharmaceutical cure for cancer becomes virtually impossible.

But, while looking for a single cure for all cancers may not be a fruitful activity, defining a best practice for understanding the genetic and protein biomarkers of individual tumors is proving worthwhile.

Continue reading “MSI Testing of Tumor Cells for Better Tailored Treatment”